Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2009;40:2849-2858
Published online before print May 14, 2009, doi: 10.1161/STROKEAHA.109.549618
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/8/2849    most recent
STROKEAHA.109.549618v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Liesz, A.
Right arrow Articles by Veltkamp, R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liesz, A.
Right arrow Articles by Veltkamp, R.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Animal models of human disease
Right arrow Apoptosis
Right arrow Acute Cerebral Infarction

(Stroke. 2009;40:2849.)
© 2009 American Heart Association, Inc.


Original Contributions

The Spectrum of Systemic Immune Alterations After Murine Focal Ischemia

Immunodepression Versus Immunomodulation

Arthur Liesz, MS; Sebastien Hagmann, MD; Carolin Zschoche, MS; Johanna Adamek, MS; Wei Zhou, MD; Li Sun, MD; Andreas Hug, MD; Markus Zorn, MSc; Alexander Dalpke, MD; Peter Nawroth, MD Roland Veltkamp, MD

From the Department of Neurology (A.L., S.H., C.Z., J.A., W.Z., L.S., A.H., R.V.), University Heidelberg, Heidelberg, Germany; the Department of Internal Medicine (M.Z., P.N.), University Heidelberg, Heidelberg, Germany; and the Department of Hygiene and Medical Microbiology (A.D.), University Heidelberg, Heidelberg, Germany.

Correspondence to Roland Veltkamp, MD, Department of Neurology, University Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail Roland.Veltkamp{at}med.uni-heidelberg.de

Background and Purpose— Therapeutic modification of the postischemic immune processes is a key target of current experimental stroke research. For successful translation into the clinical setting, experimental studies must account for the impact of different strokes on the immune system including susceptibility to infection. Herein, we characterize the impact of 3 ischemia models on systemic immunological and microbiological parameters.

Methods— In C57Bl/6 mice (n=235), the middle cerebral artery was occluded (MCAO) either permanently by distal coagulation or transiently by an intraluminal filament for 30 minutes or 90 minutes. Differential leukocyte counts were performed in blood and lymphatic organs. Lymphocyte subpopulations and apoptotic cells were characterized by flow cytometry. Blood cytokine concentrations were measured by ELISA. Microbiological cultures were grown from blood and lung samples.

Results— Only extensive infarcts induced leukopenia 24 hours, 3 days and 7 days after MCAO and decreased lymphocyte counts in spleen, lymph nodes and thymus. In contrast, small infarcts led to no significant changes in differential blood count or reduction of overall cell counts in lymphatic organs. Splenic lymphocyte apoptosis and blood cytokine production was significantly increased after extensive lesions compared to mild ischemia. Hypothermia and weight loss occurred only in mice with large infarcts which also suffered from pneumonia and sepsis. In contrast to infarct size, location and side of the infarct did not affect physiological parameters and immune cell alterations.

Conclusions— Postischemic systemic immunomodulation and infectious complications differ substantially among stroke models. Translational studies of immunomodulatory therapies for stroke must account for this heterogeneity.


Key Words: brain ischemia • immune response • leukocytes • cytokines • bacterial infection